{"filing":{"accession_number":"0001501697-26-000060","cik":"0001501697","ticker":"XFOR","company_name":"X4 Pharmaceuticals, Inc","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"xfor-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000060/xfor-20260630.htm"},"events":[{"id":15495,"run_id":13823,"accession_number":"0001501697-26-000060","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, increasing the board size from five to six directors. Ms. Gold, an experienced CFO with prior roles at Biogen and Deutsche Bank, was also appointed to the Audit Committee as an independent director.","company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13291,"accession_number":"0001501697-26-000060","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, increasing the board size from five to six directors. Ms. Gold, an experienced CFO at CAMP4 Therapeutics with prior roles at Biogen and Deutsche Bank, was also appointed to the Audit Committee. This is a clear executive appointment of a director to the board, which is material to investors assessing governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:15:08.456897+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13292,"accession_number":"0001501697-26-000060","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"X4 Pharmaceuticals announced the appointment of Kelly Gold to its Board of Directors effective July 1, 2026, as an independent director and Audit Committee member. The press release emphasizes her qualifications as an experienced CFO with biotech expertise and capital markets knowledge. Board appointments of qualified executives are material governance events affecting the registrant's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:15:08.456897+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13291,"accession_number":"0001501697-26-000060","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"X4 Pharmaceuticals appointed Kelly Gold as a Class II director effective July 1, 2026, increasing the board size from five to six directors. Ms. Gold, an experienced CFO at CAMP4 Therapeutics with prior roles at Biogen and Deutsche Bank, was also appointed to the Audit Committee. This is a clear executive appointment of a director to the board, which is material to investors assessing governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:15:08.456897+00:00","company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","filing_date":"2026-07-01"},{"id":13292,"accession_number":"0001501697-26-000060","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"X4 Pharmaceuticals announced the appointment of Kelly Gold to its Board of Directors effective July 1, 2026, as an independent director and Audit Committee member. The press release emphasizes her qualifications as an experienced CFO with biotech expertise and capital markets knowledge. Board appointments of qualified executives are material governance events affecting the registrant's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:15:08.456897+00:00","company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","filing_date":"2026-07-01"}]}